Unique ID issued by UMIN | UMIN000012895 |
---|---|
Receipt number | R000015066 |
Scientific Title | Investigation on bronchoalveolar lavage technique as an evaluation of drug migration to lung tissue |
Date of disclosure of the study information | 2014/01/18 |
Last modified on | 2014/02/06 15:58:45 |
Investigation on bronchoalveolar lavage technique as an evaluation of drug migration to lung tissue
Investigation on bronchoalveolar lavage technique as an evaluation of drug migration to lung tissue
Investigation on bronchoalveolar lavage technique as an evaluation of drug migration to lung tissue
Investigation on bronchoalveolar lavage technique as an evaluation of drug migration to lung tissue
Japan |
Respiratory Disease
Pneumology | Laboratory medicine |
Others
NO
We perform BAL in healthy male subjects
1, to investigate adequacy of BAL procedure to evaluate drug migration to lung tissue
2, to investigate precision of BAL technique by analyzing amount and component of BALF, and cell count, erythrocyte count, and differential cell count in BALF.
Others
investigation on procedure
amount and component of BALF, and cell count, erythrocyte count, and differential cell count in BALF
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
Maneuver |
bronchoalveolar lavage
20 | years-old | <= |
45 | years-old | >= |
Male
1, Healthy Japanese male.
2, Subject between 20 and 45(inclusive) year of age.
3, Subject with weight <=40kg and >80kg, and with BMI <=18.5 and =>26.0
4, Subject with no abnormality observed by physician's examinations.
5, Subjects who receives screening examinations within one month prior to the study, and the results are judged as adequate for this study by study physician.
1, Subject who has allergy or had hypersensitivity to lidocaine and/or azithromycin hydrate. And/or subject with illness which prohibits administration of these substances.
2, Subject with history of drug allergy.
3, Subject who received medical treatment 2 months prior to BAL.
4, Subject who donated more than 400ml or 200ml of blood within 3 months or 1 month prior to BAL, respectively.
5, Subject whose result of screening examinations (include vital sign, 12-lead ECG, and safety laboratory tests) deviates from reference range, and the deviation is judged clinically significant by study physician.
6, Subject who takes drug habitually and/or who abuses alcoholic beverage.
7, Subject who acquired severe medical illness within 4 months prior to BAL.
8, Subject with positive test results of syphilis, HIV antigen/antibody, HBs antigen, and/or HCV antibody. Or subject with sign of infection.
9, Subject who smokes within 6 months prior to BAL.
10, Subject who are considered to be inadequate for this study by study physician.
6
1st name | |
Middle name | |
Last name | Masanari Shiramoto |
Medical Co. LTA Hakata Clinic
Clinical Pharmacology Department
5-7F 6-18 Tenyamachi, Hakaka-ku, Fukuoka Ctiy, Fukuoka
0922837701
masanari-shiramoto@lta-med.com
1st name | |
Middle name | |
Last name | Masanari Shiramoto |
Medical Co. LTA Hakata Clinic
Clinical Pharmacology Department
5-7F 6-18 Tenyamachi, Hakaka-ku, Fukuoka Ctiy, Fukuoka
0922837701
masanari-shiramoto@lta-med.com
Medical Co. LTA Clinical Pharmacology Center
Taisho Pharmaceutical Co., Ltd.
Medical Co. LTA Hakata Clinic
Other
NO
2014 | Year | 01 | Month | 18 | Day |
Unpublished
Completed
2013 | Year | 12 | Month | 28 | Day |
2014 | Year | 01 | Month | 20 | Day |
2014 | Year | 02 | Month | 05 | Day |
2014 | Year | 01 | Month | 18 | Day |
2014 | Year | 02 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015066